[go: up one dir, main page]

CL2016001094A1 - Silicato de zirconio microporoso para el tratamiento de hipercalemia. - Google Patents

Silicato de zirconio microporoso para el tratamiento de hipercalemia.

Info

Publication number
CL2016001094A1
CL2016001094A1 CL2016001094A CL2016001094A CL2016001094A1 CL 2016001094 A1 CL2016001094 A1 CL 2016001094A1 CL 2016001094 A CL2016001094 A CL 2016001094A CL 2016001094 A CL2016001094 A CL 2016001094A CL 2016001094 A1 CL2016001094 A1 CL 2016001094A1
Authority
CL
Chile
Prior art keywords
hyperkalemia
treatment
zirconium silicate
microporous zirconium
microporous
Prior art date
Application number
CL2016001094A
Other languages
English (en)
Inventor
Donald Jeffrey Keyser
Alvaro F Guillem
Original Assignee
Zs Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zs Pharma Inc filed Critical Zs Pharma Inc
Publication of CL2016001094A1 publication Critical patent/CL2016001094A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/08—Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/14—Base exchange silicates, e.g. zeolites

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Furan Compounds (AREA)

Abstract

UNA FORMA DE DOSIFICACION FARMACEUTICA INDIVIDUAL QUE COMPRENDE ENTRE 5-15 GRAMOS DE SILICATO DE CIRCONIO MICROPOROSO, Y DONDE LA COMPOSICION PRESENTA UN CONTENIDO DE SODIO POR DEBAJO DE 12% EN PESO; PRODUCTO FARMACEUTICO QUE COMPRENDE A LA COMPOSICION, UTIL PARA EL TRATAMIENTO DE HIPERKALEMIA.
CL2016001094A 2013-11-08 2016-05-06 Silicato de zirconio microporoso para el tratamiento de hipercalemia. CL2016001094A1 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201361901886P 2013-11-08 2013-11-08
US201361914354P 2013-12-10 2013-12-10
US201461930336P 2014-01-22 2014-01-22
US201461930328P 2014-01-22 2014-01-22
US201462005484P 2014-05-30 2014-05-30
US201462015215P 2014-06-20 2014-06-20

Publications (1)

Publication Number Publication Date
CL2016001094A1 true CL2016001094A1 (es) 2016-11-11

Family

ID=53042123

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016001094A CL2016001094A1 (es) 2013-11-08 2016-05-06 Silicato de zirconio microporoso para el tratamiento de hipercalemia.

Country Status (13)

Country Link
US (2) US20160271174A1 (es)
EP (1) EP3065709A4 (es)
JP (1) JP2016535749A (es)
KR (1) KR20160110356A (es)
CN (1) CN106385795A (es)
AU (1) AU2014346572A1 (es)
CA (1) CA2929956A1 (es)
CL (1) CL2016001094A1 (es)
IL (1) IL245525A0 (es)
MX (1) MX2016005955A (es)
PH (1) PH12016500861A1 (es)
TW (1) TW201607544A (es)
WO (1) WO2015070015A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201900037T1 (it) 2011-02-11 2019-02-28 Zs Pharma Inc Uso di un silicato di zirconio per il trattamento di iperkaliemia
JP2019108282A (ja) * 2017-12-15 2019-07-04 学校法人 久留米大学 体内カリウム値の調整剤
CN113557024A (zh) * 2019-03-13 2021-10-26 阿斯利康(瑞典)有限公司 用于血液透析患者中使用的钾结合剂
US11964266B2 (en) 2019-07-09 2024-04-23 Uop Llc Process for removing cobalt, lead, cadmium and chromium ions from bodily fluids using metallate ion exchange compositions
US11577014B2 (en) 2019-07-09 2023-02-14 Uop Llc Process for removing strontium ions from bodily fluids using metallate ion exchange compositions
US11484875B2 (en) 2019-07-09 2022-11-01 Uop Llc Process for removing mercury ions from bodily fluids using titanium metallate ion exchange compositions
WO2021199239A1 (ja) * 2020-03-31 2021-10-07 興和株式会社 包装体入り含水組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4581141A (en) * 1978-02-27 1986-04-08 Purdue Research Foundation Dialysis material and method for removing uremic substances
US6804800B2 (en) * 2000-12-29 2004-10-12 Intel Corporation Method and apparatus for detecting and recovering from errors in a source synchronous bus
JP2004075612A (ja) * 2002-08-19 2004-03-11 National Agriculture & Bio-Oriented Research Organization 免疫機能増強剤
US7556799B2 (en) * 2004-03-30 2009-07-07 Relypsa, Inc. Ion binding polymers and uses thereof
WO2010068940A2 (en) * 2008-12-12 2010-06-17 Novalar Pharmaceuticals, Inc. Characterization of an antibiotic impregnated delivery system as an intracanal medicament in endodontic therapy
WO2010144865A2 (en) * 2009-06-12 2010-12-16 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
SMT201900037T1 (it) * 2011-02-11 2019-02-28 Zs Pharma Inc Uso di un silicato di zirconio per il trattamento di iperkaliemia
WO2013040082A2 (en) * 2011-09-12 2013-03-21 Medtronic, Inc. Polystyrene sulfonate resin for use with a hemodialysis system having a controlled compliance dialysis circuit

Also Published As

Publication number Publication date
CA2929956A1 (en) 2015-05-14
EP3065709A1 (en) 2016-09-14
TW201607544A (zh) 2016-03-01
JP2016535749A (ja) 2016-11-17
EP3065709A4 (en) 2017-06-14
CN106385795A (zh) 2017-02-08
US20160271174A1 (en) 2016-09-22
PH12016500861A1 (en) 2016-07-18
IL245525A0 (en) 2016-06-30
AU2014346572A1 (en) 2016-06-09
MX2016005955A (es) 2016-12-02
US20160375054A1 (en) 2016-12-29
WO2015070015A1 (en) 2015-05-14
KR20160110356A (ko) 2016-09-21

Similar Documents

Publication Publication Date Title
CL2016001094A1 (es) Silicato de zirconio microporoso para el tratamiento de hipercalemia.
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
GT201400111A (es) Triazolopiridinas sustituidas
CL2015002677A1 (es) Composiciones que comprenden selenio y uso de las mismas para el tratamiento y prevención de enfermedades o condiciones asociadas con la disfunción mitocondrial.
CL2017000136A1 (es) Composiciones de azúcar para la formación de comprimidos por compresión directa
BR112015011430A2 (pt) composição para liberação imediata e prolongada
AR098996A1 (es) Formulación compuesta para la administración por vía oral que comprende ezetimiba y rosuvastatina
MX2016003754A (es) Una composicion farmaceutica estable que contiene amlodipina y valsartan.
CO2017005544A2 (es) Tableta multicapa que contiene fármaco inestable a la luz
CL2016001587A1 (es) Derivado basado en 1,2-naftoquinona y método de preparación del mismo.
AR100365A1 (es) Composición acuosa que comprende ibuprofeno y paracetamol en combinación, proceso para fabricarla y dispositivo inyector para administrarla
CL2016001095A1 (es) Silicato de zirconio microporoso para el tratamiento de hipercalemia.
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
BR112015016033A8 (pt) composições farmacêuticas para tratamento de infecções por bactérias, e seus usos
AR090073A1 (es) N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos
BR112017001000A2 (pt) composições de açúcar para preparação de comprimidos por compressão direta
CL2016003155A1 (es) Composiciones de cuidado bucal
ECSP16060194A (es) Formas de dosificación farmacéuticas
CL2015002702A1 (es) Composiciones farmacéuticas micronizadas.
MX2017007856A (es) Composicion para el cuidado bucal.
CL2015001940A1 (es) Formulación que comprende un compuesto de benzotiazolona.
PE20170305A1 (es) Combinacion sinergistica de paracetamol/celecoxib para el tratamiento de dolor inflamatorio
WO2015044434A3 (de) FLUOR-9-METHYL-ß-CARBOLINE